trending Market Intelligence /marketintelligence/en/news-insights/trending/0QddfjCrk-SJS6pOlb7qFw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Intra-Cellular stock more than doubles after US FDA approves schizophrenia drug

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Intra-Cellular stock more than doubles after US FDA approves schizophrenia drug

The U.S. Food and Drug Administration approved Intra-Cellular Therapies Inc.'s medicine Caplyta to treat adult patients with schizophrenia.

The New York-based biopharmaceutical company's stock price more than doubled on Dec. 23 following the news. The stocks were trading at $31.50 per share on Nasdaq as of 10:11 a.m. ET, up 153.22%.

Intra-Cellular said the approval of Caplyta, or lumateperone, was backed by data from two trials which showed that the drug was better than placebo in treating adult patients with schizophrenia — a chronic and severe mental disorder that affects how a person thinks, feels and behaves. The condition affects about 2.4 million adults in the U.S., the company said in a Dec. 23 press release.

In August, the FDA had requested additional information regarding Caplyta which had received the U.S. regulator's fast-track designation in November 2017.

Intra-Cellular said the company plans to begin the commercial launch of the drug in late first quarter of 2020.